Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Inclusion Criteria: * Confirmed diagnosis of primary immune deficiency and medical records available for retrospective review for at least 3 months prior to entry into the trial * Signed an informed consent written informed consent prior to initiation of any study related procedures * Receiving regular infusions of IGIV at a fixed interval and dosage (in the range of 200-600 mg/kg given every 3-4 weeks) for at least three months prior to entry into the trial. Patients who are currently receiving less than 400 mg/kg are eligible for this trial and will be at the time of study enrollment be treated at 400 mg/kg Exclusion Criteria: * History or suspicion of significant allergic reaction to intravenous immune globulin, and/or blood products * Documented history of selective IgA deficiency (serum level \<5.0 mg/dL) and known antibodies to IgA * Isolated IgG subclass deficiency with a normal total serum IgG level * Other conditions which may interfere with the trial, include the patients demeanor or mental ability to follow instruction. * Pretreatment with anti-pyretics or anti-histamines * Congestive heart failure (New York Heart Association stage greater than Class II) * Renal insufficiency (creatinine \>2.5 mg/dL) * Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome) * Pretreatment routinely required to control/ameliorate IGIV infusion-related adverse events (AEs) * Any patient who…